ATE250138T1 - Angiogenese-inhibierende antikörper - Google Patents

Angiogenese-inhibierende antikörper

Info

Publication number
ATE250138T1
ATE250138T1 AT93923976T AT93923976T ATE250138T1 AT E250138 T1 ATE250138 T1 AT E250138T1 AT 93923976 T AT93923976 T AT 93923976T AT 93923976 T AT93923976 T AT 93923976T AT E250138 T1 ATE250138 T1 AT E250138T1
Authority
AT
Austria
Prior art keywords
pct
angiogenesis
endothelial cells
sec
date
Prior art date
Application number
AT93923976T
Other languages
English (en)
Inventor
Christopher Richard Parish
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3776506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE250138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Application granted granted Critical
Publication of ATE250138T1 publication Critical patent/ATE250138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT93923976T 1992-10-29 1993-10-29 Angiogenese-inhibierende antikörper ATE250138T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL557392 1992-10-29
PCT/AU1993/000558 WO1994010331A1 (en) 1992-10-29 1993-10-29 Angiogenesis inhibitory antibodies

Publications (1)

Publication Number Publication Date
ATE250138T1 true ATE250138T1 (de) 2003-10-15

Family

ID=3776506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923976T ATE250138T1 (de) 1992-10-29 1993-10-29 Angiogenese-inhibierende antikörper

Country Status (9)

Country Link
US (2) US5677181A (de)
EP (1) EP0669988B2 (de)
JP (1) JP3490443B2 (de)
AT (1) ATE250138T1 (de)
AU (1) AU673865B2 (de)
CA (1) CA2148244A1 (de)
DE (1) DE69333209T2 (de)
SG (1) SG78239A1 (de)
WO (1) WO1994010331A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
ES2533255T3 (es) 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
NZ508873A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR100816572B1 (ko) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
EP2298333A3 (de) * 1999-12-20 2012-05-02 Immunex Corporation Tweak Rezeptor
US6727192B2 (en) * 2001-03-01 2004-04-27 Micron Technology, Inc. Methods of metal doping a chalcogenide material
EP1432447A2 (de) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Kombinierte zusammensetzung und methoden zur behandlung der koagulation tumorgefäss
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2004024891A2 (en) * 2002-09-16 2004-03-25 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
WO2004089988A2 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
CA2530732C (en) 2003-06-27 2015-03-31 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
BRPI0509177A (pt) 2004-03-24 2007-09-18 Pdl Biopharma Inc uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
DK1819358T3 (da) 2004-11-18 2014-10-27 Imclone Llc Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
WO2006071802A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
CA2589041C (en) * 2004-12-23 2019-08-20 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
JP5289970B2 (ja) 2005-12-16 2013-09-11 エシコン・インコーポレイテッド 組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法
AU2006327073B2 (en) 2005-12-19 2012-08-30 Ethicon, Inc. In vitro expansion of postpartum derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP2193148A2 (de) * 2007-07-27 2010-06-09 Facet Biotech Corporation Einen tyrosinkinaseinhibitor und einen antikörper gegen integrin alpha 1 beta 5 (cd49e) enthaltende pharmazeutische kombination
UA99152C2 (ru) 2007-10-05 2012-07-25 Этикон, Инкорпорейтед Восстановление и регенерация почечной ткани с использованием клеток, полученных с человеческой ткани пупочного канатика
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
BRPI0923068B1 (pt) 2008-12-19 2021-05-25 Advanced Technologies And Regenerative Medicine, Llc Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar
ES2629003T3 (es) 2009-03-26 2017-08-07 DePuy Synthes Products, Inc. Células de tejido de cordón umbilical humano como tratamiento para la enfermedad de alzheimer
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US5512660A (en) * 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
JPH02502156A (ja) † 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション 内皮細胞のｒｇｄ指向粘着レセプターに対するモノクローナル抗体
EP0422186B1 (de) * 1989-04-10 1998-12-09 Oncogen Limited Partnership Verwendung von oncostatin m zur suppression von mhc antigenen
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
IT1239065B (it) * 1990-05-14 1993-09-20 Fidia Spa Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
EP0505749A3 (en) * 1991-02-26 1993-06-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper

Also Published As

Publication number Publication date
EP0669988B1 (de) 2003-09-17
DE69333209T2 (de) 2004-07-01
JP3490443B2 (ja) 2004-01-26
DE69333209D1 (de) 2003-10-23
JPH08502409A (ja) 1996-03-19
WO1994010331A1 (en) 1994-05-11
EP0669988A4 (de) 1996-07-31
EP0669988B2 (de) 2009-07-08
SG78239A1 (en) 2001-02-20
US5677181A (en) 1997-10-14
AU5366194A (en) 1994-05-24
EP0669988A1 (de) 1995-09-06
AU673865B2 (en) 1996-11-28
US5874081A (en) 1999-02-23
CA2148244A1 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
ATE250138T1 (de) Angiogenese-inhibierende antikörper
Baluna et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
Jiang et al. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
Johansson et al. Comparison of fibronectin receptors from rat hepatocytes and fibroblasts.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
DE69838454D1 (de) Natürlicher menschlicher antikörper
Boukerche et al. A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
DE59308220D1 (de) Schwungphasensteuervorrichtung
DK0703802T3 (da) Intravaginalt system til afgivelse af aktivt stof
PT861892E (pt) Epitopos das proteinas do stress
DK151687A (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
BR9707049A (pt) Agentes anticoagulantes utilizáveis no tratamento de trombose
DE69210018D1 (de) Stützkörper für eine Herzklappenprothese
KR890000101A (ko) 반월조직의 치료 개선방법 및 치료약제
EP1054687A4 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
ES2058599T3 (es) Procedimiento para mejorar la eficacia de las toxinas de insectos.
Manabe et al. Production of a monoclonal antibody-bleomycin conjugate utilizing dextran T-40 and the antigen-targeting cytotoxicity of the conjugate
DE68918944D1 (de) Künstliche rezeptor-analoge.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties